Search Orphan Drug Designations and Approvals
-
| Generic Name: | autologous CD34+ cell therapy comprised of hematopoietic stem and progenitor cells base edited with one guide RNA and a single messenger RNA encoding an adenine base editor |
|---|---|
| Date Designated: | 05/30/2025 |
| Orphan Designation: | treatment of sickle cell disease |
| Orphan Designation Status: | Designated |
| FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
| Sponsor: |
Beam Therapeutics 238 Main St Cambridge, Massachusetts 02142 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







